Negrete-Corona J, Encalada-Díaz M

Language: Spanish
References: 24
Page: 30-35
PDF size: 162.74 Kb.

ABSTRACT

Introduction: osteoarthritis is one of the most prevalent chronic diseases in the world and is defined as the gradual loss of cartilage in the joints, mainly that of the knee. It is considered a cause of disability in older adults and is characterized by pain, stiffness and loss of mobility. Material and methods: observational study to evaluate the effect of the combination of non-hydrolyzed type II native collagen (CII-NH), omega-3 (Om-3) and astaxanthin (AX), in a population of 182 patients with knee osteoarthritis grade I/II. Measurements of thigh circumference, arcs of movement and pain were obtained through international scales such as the visual analogue pain scale (VAS), the Lequesne index and the Western Ontario McMaster Universities Osteoarthritis Index (WOMAC) scale. Medical check-ups were performed every 30 days for three months. The Statgraphics software (Statgraphics Technologies, Virginia) was used, the evaluation of the variables and the statistical significance were determined by t Student test and the results are shown as a mean. Results: it was shown that daily consumption increases mobility, decreases knee pain and inflammation in patients within three months. Additionally, there was a reduction in the consumption of nonsteroidal anti-inflammatory drugs (NSAIDs) by the study subjects. Conclusion: the fixed combination of non-hydrolyzed type II collagen, omega-3 and astaxanthin, generates, in the short term, a decrease in inflammation and stiffness in patients with osteoarthritis.

REFERENCES

1. Puig-Junoy J, Ruiz Zamora A. Socio-economic costs of osteoarthritis: a systematic review of cost-of-illness studies. Semin Arthritis Rheum. 2015; 44(5): 531-41. doi: 10.1016/j.semarthrit.2014.10.012.

2. Lane NE, Brandt K, Hawker G, Peeva E, Schreyer E, Tsuji W, et al. OARSI-FDA initiative: defining the disease state of osteoarthritis. Osteoarthritis Cartilage. 2011; 19(5): 478-82. doi: 10.1016/j.joca.2010.09.013.

3. Peña Ayala AH, Fernández-López JC. Prevalencia y factores de riesgo de la osteoartritis. Reumatol Clin. 2007; 3 Supl 3: S6-12.

4. Cui A, Li H, Wang D, Zhong J, Chen Y, Lu H. Global, regional prevalence, incidence and risk factors of knee osteoarthritis in population-based studies. EClinicalMedicine. 2020; 29-30: 100587. doi: 10.1016/j.eclinm.2020.100587.

5. Hijos-Mallada G, Sostres C, Gomollón F. NSAIDs, gastrointestinal toxicity and inflammatory bowel disease. Gastroenterol Hepatol. 2022; 45(3): 215-22. doi: 10.1016/j.gastrohep.2021.06.003.

6. Quintero Carrión E. Efectos de los AINE sobre la mucosa gastrointestinal. Rev Esp Reumatol. 2000; 27(1): 19-24.

7. Liu X, Machado GC, Eyles JP, Ravi V, Hunter DJ. Dietary supplements for treating osteoarthritis: a systematic review and meta-analysis. Br J Sports Med. 2018; 52(3): 167-75. doi: 10.1136/bjsports-2016-097333.

8. García-Coronado JM, Martínez-Olvera L, Elizondo-Omaña RE, Acosta-Olivo CA, Vilchez-Cavazos F, Simental-Mendía LE, et al. Effect of collagen supplementation on osteoarthritis symptoms: a meta-analysis of randomized placebo-controlled trials. Int Orthop. 2019; 43(3): 531-8. doi: 10.1007/s00264-018-4211-5.

9. Gencoglu H, Orhan C, Sahin E, Sahin K. Undenatured type II collagen (UC-II) in joint health and disease: a review on the current knowledge of companion animals. Animals (Basel). 2020; 10(4): 697. doi: 10.3390/ani10040697.

10. Lugo JP, Saiyed ZM, Lane NE. Efficacy and tolerability of an undenatured type II collagen supplement in modulating knee osteoarthritis symptoms: a multicenter randomized, double-blind, placebo-controlled study. Nutr J. 2016; 15: 14.

11. Crowley DC, Lau FC, Sharma P, Evans M, Guthrie N, Bagchi M, et al. Safety and efficacy of undenatured type II collagen in the treatment of osteoarthritis of the knee: a clinical trial. Int J Med Sci. 2009; 6(6): 312-21.

12. Bakilan F, Armagan O, Ozgen M, Tascioglu F, Bolluk O, Alatas O. Effects of native type II collagen treatment on knee osteoarthritis: a randomized controlled trial. Eurasian J Med. 2016; 48(2): 95-101.

13. Goldberg RJ, Katz J. A meta-analysis of the analgesic effects of omega-3 polyunsaturated fatty acid supplementation for inflammatory joint pain. Pain. 2007; 129(1-2): 210-23.

14. Lee YH, Bae SC, Song GG. Omega-3 polyunsaturated fatty acids and the treatment of rheumatoid arthritis: a meta-analysis. Arch Med Res. 2012; 43(5): 356-62.

15. Akbar U, Yang M, Kurian D, Mohan C. Omega-3 fatty acids in rheumatic diseases: a critical review. J Clin Rheumatol. 2017; 23(6): 330-9.

16. Ioan-Facsinay A, Kloppenburg M. Bioactive lipids in osteoarthritis: risk or benefit? Curr Opin Rheumatol. 2018; 30(1): 108-13.

17. Zhang X, Hou Y, Li J, Wang J. The role of astaxanthin on chronic diseases. Crystals (Basel). 2021; 11(5): 505.

18. López Roldan P, Mach N. Efecto del consumo de astaxantina en la salud. Rev Esp Nutr Comunitaria. 2012; 18(3): 164-77.

19. Fakhri S, Abbaszadeh F, Dargahi L, Jorjani M. Astaxanthin: A mechanistic review on its biological activities and health benefits. Pharmacol Res. 2018; 136: 1-20.

20. Guerin M, Huntley ME, Olaizola M. Haematococcus astaxanthin: applications for human health and nutrition. Trends Biotechnol. 2003; 21(5): 210-6.

21. Higuera-Ciapara I, Félix-Valenzuela L, Goycoolea FM. Astaxanthin: a review of its chemistry and applications. Crit Rev Food Sci Nutr. 2006; 46(2): 185-96.

22. Biswal S. Oxidative stress and astaxanthin: The novel supernutrient carotenoid. Int J Health Allied Sci. 2014; 3: 147-53.

23. Zuart-Alvarado R, Martínez-Torres J. Osteoartrosis y patologías crónicas asociadas en pacientes de una unidad médica del primer nivel. Rev Med Inst Mex Seguro Soc. 2011; 49(6): 637-42.

24. Pérez Martín A. Symptoms. Localizations: knee, hip, hands, spine, other localizations. Aten Primaria. 2014; 46 Suppl 1(Suppl 1): 11-7. doi: 10.1016/S0212-6567(14)70038-1.

EVIDENCE LEVEL

IV serie de casos.